Clinical Trial Update: To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of R932348 ophthalmic solution in patients with Keratoconjunctivitis Sicca; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• R932348 ophthalmic solution (R932348)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Keratoconjunctivitis Sicca | Phase 2 | Status: COMPLETED | Results posted: 2016-10-03